Economic Evaluation of Nivolumab as a Second-Line Treatment for Advanced Renal Cell Carcinoma From US and Chinese Perspectives

Cancer - United States
doi 10.1002/cncr.30666
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy